Exosomes are small extracellular nanovesicles that are released by cells, and their potential has been explored for use in cosmetics, skin care, tissue regeneration, and dermatological diseases. The therapeutic value of exosomes lies in their ability to modulate the microenvironment of cells, regulate gene expression, and induce cell differentiation, which can have a positive impact on skin health. In terms of cosmetics, exosomes have been used to reduce wrinkles, improve skin texture and hydration, and enhance skin elasticity, as well as to reduce inflammation and damage caused by UV radiation. Furthermore, exosomes have been used to promote tissue regeneration in skin wounds and to treat dermatological diseases such as systemic lupus erythematosus, psoriasis, atopic dermatitis, systemic sclerosis, pigment regulation, vitiligo, and hair growth. In this review, the therapeutic value of exosomes in the field of cosmetics, skin care, tissue regeneration, and dermatological diseases, has been elaborated. The existing literature demonstrated that with further research, exosomes may become a viable therapeutic option for many skin conditions.

Glioblastoma (GBM) is a fatal adult brain tumor with an extremely poor prognosis. GBM poses significant challenges for targeted therapies due to its intra- and inter-tumoral heterogeneity, a highly immunosuppressive microenvironment, diffuse infiltration into normal brain parenchyma, protection by the blood-brain barrier and acquisition of therapeutic resistance. Recent studies have implicated epigenetic modifiers as key players driving tumorigenesis, resistance, and progression of GBM. While the vast majority of GBM research on epigenetic modifiers thus far has focused predominantly on elucidating the functional roles and targeting of DNA methyltransferases and histone deacetylases, emerging evidence indicates that histone acetyltransferases (HATs) also play a key role in mediating plasticity and therapeutic resistance in GBM. Here, we will provide an overview of HATs, their dual roles and functions in cancer as both tumor suppressors and oncogenes and focus specifically on their implications in GBM resistance. We also discuss the technical challenges in developing selective HAT inhibitors and highlight their promise as potential anti-cancer therapeutics for treating intractable cancers such as GBM.

Facile and efficient early detection of cancer is a major challenge in healthcare. Herein we developed a novel sensor made from a polycarbonate (PC) membrane with nanopores, followed by sequence-specific Oligo RNA modification for early gastric carcinoma diagnosis. In this design, the gastric cancer antigen CA72-4 is specifically conjugated to the Oligo RNA, thereby inhibiting the electrical current through the PC membrane in a concentration-dependent manner. The device can determine the concentration of cancer antigen CA72-4 in the range from 4 to 14 U/mL, possessing a sensitivity of 7.029 µAU⁻¹mLcm⁻² with a linear regression (R²) of 0.965 and a lower detection limit of 4 U/mL. This device has integrated advantages including high specificity and sensitivity and being simple, portable, and cost effective, which collectively enables a giant leap for cancer screening technologies towards clinical use. This is the first report to use RNA aptamers to detect CA72-4 for gastric carcinoma diagnosis.